Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 111

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer

Lyu, Haoyu, Li, Mengyuan, Jiang, Zehang, Liu, Zhixian, Wang, Xiaosheng · 2019 · Computational and Structural Biotechnology Journal

Abstract

Although immunotherapy has emerged as an effective therapeutic strategy for various cancers including head and neck squamous cell carcinomas (HNSCCs), only a subset of patients can benefit from such therapy. Hence, it is pressing to discover predictive biomarkers for cancer immunotherapy response. TP53 and HRAS mutations frequently occur in HNSCC and correlate with a worse prognosis in HNSCC. We extensively characterized the associations of TP53 mutations and HRAS mutations with HNSCC immunity based on multiple cancer genomics datasets. We compared the enrichment levels of 20 immune signatures between TP53-mutated and TP53-wildtype HNSCCs, and between HRAS-mutated and HRAS-wildtype HNSCCs, and found that TP53 mutations were associated with depressed immune signatures while HRAS mutations were associated with enhanced immune signatures in HNSCC. Moreover, we found multiple p53- and RAS-mediated pathways showing significant correlations with HNSCC immunity. Furthermore, we demonstrated that the association between TP53 mutation and tumor immunity was independent of the human papillomavirus (HPV) infection and smoking status in HNSCC. These data suggest that p53 and RAS may play important roles in regulating HNSCC immunity and that the TP53 and HRAS mutation status could be useful biomarkers for stratifying HNSCC patients responsive to immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.csbj.2019.07.009

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 35

  1. 10.1002/ijc.25516 · DOI · Paper page
  2. Addeo R., Caraglia M. and Iuliano G.: Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opin Biol Ther 2016; 16: 1075. · DOI
  3. Li X., Shao C., Shi Y. and Han W.: Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol 2018; 11: 31. · DOI · Paper page
  4. 10.1158/1078-0432.CCR-16-0066 · DOI · Paper page
  5. 10.1056/NEJMoa1406498 · DOI · Paper page
  6. 10.1126/science.aaa1348 · DOI · Paper page
  7. 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
  8. 10.1056/NEJMoa1500596 · DOI · Paper page
  9. 10.18632/oncotarget.13483 · DOI
  10. Cancer Genome Atlas N : Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576. · DOI · Paper page
  11. Zitvogel L. and Kroemer G.: CANCER. A p53-regulated immune checkpoint relevant to cancer. Science 2015; 349: 476. · DOI
  12. 10.1158/0008-5472.CAN-11-4134 · DOI · Paper page
  13. 10.1016/j.immuni.2017.11.016 · DOI · Paper page
  14. 10.1007/s00262-017-2005-z · DOI · Paper page
  15. 10.1002/ijc.29649 · DOI · Paper page
  16. 10.1097/CCO.0000000000000234 · DOI
  17. 10.1038/264145a0 · doi:10.1038/264145a0
  18. Wang B., Niu D., Lai L. and Ren E.C.: p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun 2013; 4: 2359. · DOI
  19. Davoli T., Uno H., Wooten E.C. and Elledge S.J.: Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017; 355. · DOI · Paper page
  20. Fritsch E.F., Hacohen N. and Wu C.J.: Personal neoantigen cancer vaccines: the momentum builds. Oncoimmunology 2014; 3: e29311. · DOI
  21. 10.1111/ejh.12427 · DOI · Paper page
  22. 10.1038/35021086 · DOI · Paper page
  23. Vrba L., Junk D.J., Novak P. and Futscher B.W.: p53 induces distinct epigenetic states at its direct target promoters. BMC Genomics 2008; 9: 486. · DOI
  24. 10.1034/j.1600-065X.2003.00015.x · DOI · Paper page
  25. Ben Safta T., Ziani L., Favre L., Lamendour L., Gros G. et al: Granzyme B-activated p53 interacts with Bcl-2 to promote cytotoxic lymphocyte-mediated apoptosis. J Immunol 2015; 194: 418. · DOI
  26. 10.1074/jbc.275.10.7337 · DOI · Paper page
  27. 10.1016/j.tranon.2016.10.005 · doi:10.1016/j.tranon.2016.10.005
  28. 10.1186/s40425-016-0165-6 · DOI · Paper page
  29. 10.1038/bjc.2011.189 · DOI · Paper page
  30. 10.1016/j.tranon.2018.07.012 · DOI · Paper page
  31. 10.1080/14712598.2017.1309387 · DOI
  32. 10.1016/j.immuni.2016.10.021 · DOI · Paper page
  33. 10.1038/nature08460 · DOI · Paper page
  34. 10.1038/nbt.2203 · DOI · Paper page
  35. Kim S.: Ppcor: an R package for a fast calculation to semi-partial correlation coefficients. Commun Stat Appl Methods 2015; 22: 665.

Cited by

See all 111

Metadata

Authors
Lyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X.
Affiliations
Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China
Venue
Computational and Structural Biotechnology Journal
Published
2019-01
Volume
17
Pages
1020-1030
ISSN
2001-0370
Cited by
111
References
20
Language
en
Licence
Funders
China Pharmaceutical University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.